MAHONEY DAVID L sold $1.7M of CORT (indirect holdings)

MAHONEY DAVID L sold 20,000 indirectly-held shares of CORCEPT THERAPEUTICS INC (CORT) at $84.53 ($1.69M total) on 2026-06-17.

Original reporting
SEC EDGAR · MAHONEY DAVID L
Published Jun 18, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
medium confidence
Mentioned
$CORT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The newest fact is the reported sale of 20,000 shares (~$1.69M) on 2026-06-17, with holdings after the transaction at 26,147 shares and no pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but this filing alone is not a fundamental catalyst.

03

What to watch

No context on total holdings, tax events, or whether other insiders are selling/buying around the same period; without that, the signal is weak.

Relevance 6/10Novelty 5/10Timing: Form 4 filed 2026-06-18 for a sale executed 2026-06-17

Background

SEC Form 4 insider transaction disclosure for Corcept Therapeutics (director David L. Mahoney).

Company-level read

Ticker impact

$CORTNeutralMedium confidence
Context

Corcept Therapeutics director David L. Mahoney filed a Form 4 reporting an indirect open-market sale of 20,000 shares at $84.5253 on 2026-06-17.

Expected impact

Low likelihood of a sustained price move; any impact would be short-lived unless accompanied by broader insider selling or new company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction with no 10b5-1 plan and a disclosed sale size (~$1.69M). However, insider sales are common and the article provides no new operational/regulatory/financial catalyst.

Market effects

Minimal; this is company-specific insider activity with no sector-wide signal provided.

None indicated.

None indicated.

Counterpoint

The sale is indirect and may reflect diversification/liquidity needs rather than a bearish view; absence of a 10b5-1 plan does not necessarily imply negative information.

Key entities

  • CORCEPT THERAPEUTICS INC

    Subject of the Form 4 insider transaction; director reported an indirect open-market sale.

  • MAHONEY DAVID L

    Director who reported the sale; transaction code S (open-market sale).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.